Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag. (Funded by Novartis; VAYHIT2 ClinicalTrials.gov number, NCT05653219.).
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 0
- Publications
- 1
- Citations
- 0
- Institution
- Istituti di Ricovero e Cura a Carattere Scientifico
External Links
Identifiers
- ORCID
- 0000-0001-9152-435X
Impact Metrics
h-index
0
h-index: Number of publications with at least h citations each.